Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on Abrocitinib PK in Healthy Subjects
NCT03637790Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoints: Plasma PF-04965842 Maximum Observed Concentration and Area Under the Curve From Zero to Infinity. Started Sep 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03637790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637790.